Leniolisib (phosphate)

• UNSPSC Description:

  Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.

• Target Antigen:

  PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/leniolisib-phosphate.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CCC(N1C[C@H](CC1)NC2=C3CN(CCC3=NC=N2)C4=CC(C(F)(F)F)=C(N=C4)OC)=O.O=P(O)(O)O

• Molecular Weight:

  548.45

• References & Citations:

  [1]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[2]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  1354691-97-6